A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD (PHTHALO-205)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04331730|
Recruitment Status : Completed
First Posted : April 2, 2020
Results First Posted : October 26, 2022
Last Update Posted : October 26, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Neovascular Age-related Macular Degeneration||Drug: AKST4290 Drug: Placebo Drug: Aflibercept||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||107 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration|
|Actual Study Start Date :||January 28, 2020|
|Actual Primary Completion Date :||August 19, 2021|
|Actual Study Completion Date :||September 16, 2021|
Experimental: AKST4290 (800 mg) + Aflibercept
Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
Aflibercept intravitreal injection
Experimental: AKST4290 (1600 mg) + Aflibercept
Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
Aflibercept intravitreal injection
Placebo Comparator: Placebo + Aflibercept
Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment
Aflibercept intravitreal injection
- Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Per the Early Treatment Diabetic Retinopathy Study (ETDRS) Testing Method [ Time Frame: Baseline to Week 36 ]Mean change from baseline in Best Corrected Visual Acuity (BCVA) per the Early Treatment Diabetic Retinopathy Study (ETDRS) testing method. BCVA will be assessed using ETDRS charts at 4 meters initial testing distance and assessed in both eyes. Score range is 0 to 93. A higher score indicates better vision.
- Time to PRN Injection (Arms 1 and 2 Only) [ Time Frame: Baseline to Week 36 ]Time to first use of intravitreal aflibercept injection, as needed (AKST4290 Arms only). UNITS: weeks.
- Median Number of Aflibercept Injections Received Beginning at Week 12 [ Time Frame: Week 12 to Week 36 ]Median number of injections received beginning at Week 12 as a rate. UNITS: number of injections per week from Week 12
- Percentage of Subjects With Best Corrected Visual Acuity (BCVA) Change of ≥ 15 Letters [ Time Frame: Baseline to Week 36 ]Percentage of subjects with Best Corrected Visual Acuity (BCVA) change of ≥ 15 letters at Week 36.
- Mean Change in Central Subfield Thickness (CST) Compared With Control Through Week 12 [ Time Frame: Baseline to Week 12 ]Mean change in Central Subfield Thickness (CST) compared with control through Week 12. UNITS: micrometre
- Number of Participants With Adverse Events Assessed by Intensity [ Time Frame: Screening to Week 40 ]Number of Participants with Adverse Events categorized by intensity
- Mean Change in Best Corrected Visual Acuity (BCVA) Per the Early Treatment Diabetic Retinopathy Study (ETDRS) Testing Method as Compared With Control [ Time Frame: Week 12 to Week 36 ]Mean change in Best Corrected Visual Acuity (BCVA) letter score per the Early Treatment Diabetic Retinopathy Study (ETDRS) testing method from Week 12 as compared to control at Week 36. BCVA will be assessed using ETDRS charts at 4 meters initial testing distance and assessed in both eyes. Score range is 0 to 93. A higher score indicates better vision.
- Time to the First Visit Where PRN Injection Criteria Are Met [ Time Frame: Week 12 to the first visit meeting PRN injection criteria through week 36 ]Time to the first visit where PRN injection criteria are met starting at Week 12 will be calculated in weeks as the first date where PRN injection criteria are first met minus the date of first dose of study drug plus one, divided by seven. Subjects who do not experience the event of interest (meet the criteria for PRN IAI) while on the study will be censored at their last visit completed through Week 36. Units: weeks
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||50 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Key Inclusion Criteria:
Men and women with newly diagnosed active Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD), diagnosed by a retinal specialist with all the following characteristics and ophthalmic inclusion criteria applied to the study eye, as assessed by a central reader:
- Has been examined by a retinal specialist and found to be eligible to receive Intravitreal Aflibercept Injection (IAI) in the study eye.
- No prior treatment for Neovascular Age-Related Macular Degeneration (nAMD) in the study eye.
- Study eye has not undergone pars plana vitrectomy or glaucoma filtering surgery.
- Participation in studies of investigational drugs must have been discontinued within 30 days or 5 half-lives of the drug (whichever was longer) prior to screening.
- Central subfield thickness (CST) thickness ≥ 250 microns on SD-OCT (spectral domain OCT) (exclusive of subretinal pigment epithelial fluid, inclusive of SRF).
- Presence of SRF (subretinal fluid) and/or IRF (intraretinal fluid) on SD-OCT.
- Total lesion size not greater than 12 disc areas (30.48 mm2) (1 disc area = 2.54 mm2) on FA (fluorescein angiography).
- If present, subretinal hemorrhage must comprise < 50% of the total lesion area on FA, SD-OCT, or FP/FAF (fundus photography/fundus autofluorescence).
- No subfoveal fibrosis or atrophy on FA, SD-OCT, or FP/FAF.
- Active CNV (choroidal neovascularization) membranes with subfoveal leakage or juxtafoveal leakage too close for laser photocoagulation.
- BCVA (Best Corrected Visual Acuity) in the study eye between 70 and 24 letters inclusive.
- Body mass index (BMI) between (and inclusive of) 18 and 40 at screening.
Key Exclusion Criteria:
- Participation in studies of investigational drugs within 30 days or 5 half-lives of the drug (whichever was longer) prior to screening.
- Known hypersensitivity to the active substance or any of the excipients of AKST4290 or aflibercept.
- Active or suspected ocular or periocular infection and/or active, severe intraocular inflammation.
- Any form of macular degeneration that is not age-related (e.g., Best's disease, Stargardt's disease, Sorsby's disease).
- Additional disease in the study eye that could compromise BCVA (i.e., uncontrolled glaucoma (IOP >24) with visual field loss, clinically significant diabetic macular edema, history of ischemic optic neuropathy or retinal vascular occlusion, vitreomacular traction, high myopia > 6 diopters, or genetic disorders such as retinitis pigmentosa).
- Presence of RPE (Retinal Pigment Epithelium) tears or rips in the study eye.
- Anterior segment and vitreous abnormalities in the study eye that would preclude adequate visualization with FP/FAF, FA, or SD-OCT.
- Intraocular surgery in the study eye within 3 months prior to screening.
- Aphakia or total absence of the posterior capsule (yttrium aluminum garnet [YAG] laser capsulotomy permitted in an eye with a posterior chamber intraocular lens if performed a minimum of 1 month prior to enrollment) in the study eye.
- Known allergy to fluorescein sodium.
- Significant alcohol or drug abuse within past 2 years.
- Based on ECG (electrocardiogram) reading, subjects with a risk of QT prolongation.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04331730
|Study Director:||Alkahest Medical Monitor||Alkahest, Inc.|
Documents provided by Alkahest, Inc.:
|Responsible Party:||Alkahest, Inc.|
|Other Study ID Numbers:||
|First Posted:||April 2, 2020 Key Record Dates|
|Results First Posted:||October 26, 2022|
|Last Update Posted:||October 26, 2022|
|Last Verified:||October 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Wet Macular Degeneration
Angiogenesis Modulating Agents
Physiological Effects of Drugs